Tesla is one of the three most shorted U.S. auto stocks
SAN DIEGO—Brett Sandercock, the Chief Financial Officer of ResMed Inc . (NYSE:RMD), executed a stock sale on May 22, 2025, under a prearranged trading plan. Sandercock sold 3,644 shares of ResMed common stock at a price of $244.59 per share, amounting to a total transaction value of $891,285. The transaction occurred as ResMed’s stock trades near its 52-week high of $263.05, with the company maintaining a robust market capitalization of $36 billion. According to InvestingPro analysis, ResMed currently shows a "GREAT" financial health score.
Following this sale, Sandercock retains ownership of 86,283 shares. The transaction was part of a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling company stock. Additionally, his remaining shares include those acquired through the ResMed Employee Stock Purchase Plan. InvestingPro data reveals ResMed has maintained dividend payments for 14 consecutive years with a 10.4% dividend growth in the last twelve months. For deeper insights into ResMed’s insider trading patterns and comprehensive financial analysis, investors can access the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, ResMed’s fiscal third-quarter 2025 results have drawn significant attention. The company reported a revenue of $1.29 billion, reflecting a 9% year-over-year increase, with strong performance in the Masks & Accessories segment. However, ResMed’s earnings per share (EPS) slightly missed consensus estimates, coming in at $2.37. Analysts have varied in their outlooks following these results. UBS maintained a Buy rating with a $285 price target, citing the promising developments in sleep apnea treatment trials by Apnimed. Stifel kept a Hold rating with a $240 target, expressing concerns over potential challenges related to GLP-1. RBC Capital raised its price target to $255, maintaining a Sector Perform rating, while Piper Sandler lowered its target to $248, citing mixed quarterly results. KeyBanc increased its target to $274, highlighting the company’s strong market position and tariff exemptions. These recent developments are pivotal for investors monitoring ResMed’s strategic and financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.